Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

/in /by

Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.

Read more

Smart bra set to detect breast cancer

/in /by

A French-Swiss research team is developing a “smart bra” for detecting breast cancer more accessible than through mammography.

Read more

GARDP wants five AMR breakers by 2025

/in /by

GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.

Read more

Genfit in $228m deal with Terns Pharmaceuticals

/in /by

Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor  to Terns Pharmaceuticals Inc.
                                                                           

Read more

Karo Pharma acquires Trimb AB

/in /by

Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).

Read more

GM proponents grill German government

/in /by

German GM proponents have taken action against discrimination of food products generated by gene editing.

Read more